-transparent.png){kind=logo}
The interaction of methotrexate and/or cyclophosphamide with the pharmacokinetics of 5-fluorouracil (5-FU) was studied in tumor-bearing WAG/Rij rats. Four groups were formed including treatment with single-agent 5-FU (eight rats); 5-FU plus methotrexate (11 rats); 5-FU plus cyclophosphamide (12 rats); and 5-FU, cyclophosphamide, and methotrexate (13 rats). The area-under-the-plasma-concentration/time curve, total-body clearance, elimination half-life, mean residence time, and steady-state volume of distribution were computed and compared. The mean residence time and elimination half-life of 5-FU increased when methotrexate was included in the combination. The increase was significant (P less than 0.05) for 5-FU, cyclophosphamide, and methotrexate versus 5-FU and cyclophosphamide.
E A de Bruijn, and
O Driessen, and
P Leeflang, and
E van Strijen, and
N van den Bosch, and
J Hermans
May 2002,
European journal of cancer (Oxford, England : 1990),
E A de Bruijn, and
O Driessen, and
P Leeflang, and
E van Strijen, and
N van den Bosch, and
J Hermans
November 1975,
Cancer,
E A de Bruijn, and
O Driessen, and
P Leeflang, and
E van Strijen, and
N van den Bosch, and
J Hermans
January 1984,
International journal of radiation oncology, biology, physics,
E A de Bruijn, and
O Driessen, and
P Leeflang, and
E van Strijen, and
N van den Bosch, and
J Hermans
January 1979,
Cancer,
E A de Bruijn, and
O Driessen, and
P Leeflang, and
E van Strijen, and
N van den Bosch, and
J Hermans
March 1980,
Minerva medica,
E A de Bruijn, and
O Driessen, and
P Leeflang, and
E van Strijen, and
N van den Bosch, and
J Hermans
April 2012,
European review for medical and pharmacological sciences,
E A de Bruijn, and
O Driessen, and
P Leeflang, and
E van Strijen, and
N van den Bosch, and
J Hermans
October 1988,
Pharmaceutisch weekblad. Scientific edition,
E A de Bruijn, and
O Driessen, and
P Leeflang, and
E van Strijen, and
N van den Bosch, and
J Hermans
January 1986,
Drugs under experimental and clinical research,
E A de Bruijn, and
O Driessen, and
P Leeflang, and
E van Strijen, and
N van den Bosch, and
J Hermans
September 2011,
Journal of breast cancer,
E A de Bruijn, and
O Driessen, and
P Leeflang, and
E van Strijen, and
N van den Bosch, and
J Hermans
January 1990,
Cancer investigation,
